Interventional Cardiology

Delivering Meaningful Innovation

A Pioneering Alternative to Blood Thinners. The WATCHMAN™ Left Atrial Appendage Closure Device is the only FDA-approved heart implant proven to reduce stroke risk in patients with non-valvular atrial fibrillation who need an alternative to long-term blood thinners. The WATCHMAN device is covered by Medicare and Medicaid Services for patients meeting certain coverage criteria. 

Healing with Confidence. The SYNERGY™ Bioabsorbable Polymer Stent System is the first and only FDA-approved stent with a fast-absorbing bioabsorbable polymer coating to enable rapid healing and provide freedom from long-term polymer exposure. SYNERGY BP Stent is a meaningful step forward in drug-eluting stent technology.

Designed to Optimize TAVR. The ACURATE neo^TM Aoritic Valve System* is a transcatheter aortic valve replacement (TAVR) technology that is designed to treat patients suffering from severe and symptomatic aortic valve stenosis who are considered at high risk for surgical valve replacement.

*The ACURATE neo^TM Aortic Valve System is CE Marked. It is not available for sale or use in the U.S.

• Cardiovascular Diseases
• Coronary Artery Disease
• Acute Myocardial Infarction

• Drug-Eluting Stents
• Bare-Metal Stents
• Catheters
• Balloons
• Guide Wires
• Atherectomy
• Thrombectomy
• Intravascular Ultrasound (IVUS)
• Fractional Flow Reserve (FFR)
• Transcatheter Aortic Valve Replacement (TAVR)
• Left Atrial Appendage Closure (LAAC)
  
   

Sources

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update. A report from the American Heart Association. Circulation 2014; 129: e28-e292.

2. Colilla et al. Am J Cardiology, 2013; 112:1142-1147.

3. Holmes, DR et al. Seminars in Neurology, 2010; 30:528–536.